Liver Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our clinics, this assemblage of "best practice tools" has been well received by patients and surrogates enabling us to increase the number of outpatients with cirrhosis who have actively contributed to their GCD before acute health events and are supported by well-informed surrogates.(Hepatology 2018;67:2025-2040).
|
29251778 |
2018 |
Movement Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
GCDH gene mutation can lead to glutaric acid and 3- OH glutaric acid accumulation, with clinical manifestation of neuronal damage, brain atrophy, microencephalic macrocephaly, decreased coordination of swallowing, poor muscle coordination, spasticity, and severe dystonic movement disorder.
|
29458885 |
2018 |
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our clinics, this assemblage of "best practice tools" has been well received by patients and surrogates enabling us to increase the number of outpatients with cirrhosis who have actively contributed to their GCD before acute health events and are supported by well-informed surrogates.(Hepatology 2018;67:2025-2040).
|
29251778 |
2018 |
Lattice corneal dystrophy Type I
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
GCD variants show biophysical profiles distinct from those of LCD mutations.
|
29524512 |
2018 |
Colorectal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, we analyzed 16 CRCs for the presence of intra-tumor heterogeneity (ITH) and found that two CRCs harbored regional ITH for GCDH frameshift mutations.
|
25450519 |
2014 |
Fleck corneal dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that a subset of FCD type IIIa (namely abnormal cortical layering associated with MTS and GCD type 2) exists in which loss of Reelin appears to be the common pathogenetic basis.
|
22203331 |
2012 |
Metabolic Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Glutaric acidemia type 1 (GA1) is a metabolic disease caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH).
|
21176883 |
2011 |
Corneal dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Five mutations of TGFBI were identified in 21 families with CDs, including one novel small deletion mutation, c.delta1838-1849 (p.Delta613-616VAEP), responsible for one variant lattice CD (LCD) family and 4 known mutations, R555W mutation for 10 granular cornea dystrophy type I (GCD1) families, R124H for 5 GCD type II (GCD2), R124C for 4 LCD1, and H626R for one variant LCD.
|
20664689 |
2010 |
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
The latter has been successfully applied to patients with different neurological disease states not including glutaryl-CoA dehydrogenase (GCDH) deficiency.
|
15505395 |
2004 |
D-2-HYDROXYGLUTARIC ACIDURIA 1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, sequence analysis of the GCDH gene in 8 additional unrelated patients with D-2-HGA and 3 with combined D/ L-2-HGA did not reveal any pathogenic mutations.
|
15248096 |
2004 |
Neurologic Symptoms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Glutaric acidemia type I (GAI) (McKusick 231670) is an autosomal recessive disease affecting the catabolism of the amino acids lysine, hydroxylysine and tryptophan, caused by a defect in the gene encoding glutaryl-coenzyme A dehydrogenase (GCDH) and associated with severe neurological symptoms.
|
9600243 |
1998 |
Avellino corneal dystrophy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Granular corneal dystrophy type II (GCD II) is an autosomal dominant disorder characterized by age-dependent progressive accumulation of transforming growth factor-beta-induced protein (TGFBIp) deposits in the corneal stroma.
|
19497990 |
2009 |
Avellino corneal dystrophy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The present study investigated the effect of mitomycin C (MMC) on cell viability, apoptosis, and transforming growth factor beta-induced protein (TGFBIp) expression in cultured normal corneal fibroblasts and heterozygote or homozygote granular corneal dystrophy type II (GCD II) corneal fibroblasts.
|
18615204 |
2008 |
Inborn Errors of Metabolism
|
0.030 |
Biomarker
|
group |
BEFREE |
Glutaric acidemia type I (GA-1) is an inborn error of metabolism due to deficiency of glutaryl-CoA dehydrogenase (GCDH), which catalyzes the conversion of glutaryl-CoA to crotonyl-CoA.
|
30203563 |
2019 |
Dystonia Disorders
|
0.030 |
GeneticVariation
|
group |
BEFREE |
We conclude that both GCDH activity and GCDH mutation analysis should be considered in the differential diagnosis of progressive forms of early-onset generalized dystonia and that mitochondrial fatty acid metabolism is one important pathway in the development of dystonia.
|
21912879 |
2012 |
Inborn Errors of Metabolism
|
0.030 |
Biomarker
|
group |
BEFREE |
Glutaryl-CoA dehydrogenase (GCDH) deficiency causes glutaric academia type I (GA-I), an inborn error of metabolism that is characterized clinically by dystonia and dyskinesia and pathologically by neural degeneration of the caudate nucleus and putamen.
|
15318278 |
2004 |
Dystonia Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Glutaryl-CoA dehydrogenase (GCDH) deficiency causes glutaric academia type I (GA-I), an inborn error of metabolism that is characterized clinically by dystonia and dyskinesia and pathologically by neural degeneration of the caudate nucleus and putamen.
|
15318278 |
2004 |
Inborn Errors of Metabolism
|
0.030 |
Biomarker
|
group |
BEFREE |
Glutaryl-CoA dehydrogenase (GCDH) deficiency causes glutaric aciduria type I (GA I), an inborn error of metabolism that is characterized clinically by dystonia and dyskinesia and pathologically by neural degeneration of the caudate and putamen.
|
10960496 |
2000 |
Dystonia Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Glutaryl-CoA dehydrogenase (GCDH) deficiency causes glutaric aciduria type I (GA I), an inborn error of metabolism that is characterized clinically by dystonia and dyskinesia and pathologically by neural degeneration of the caudate and putamen.
|
10960496 |
2000 |
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |